The Disruptors: The Next Wave of Promising Psychiatry and Neurology Drugs

Drugs that target the brain are among the most challenging to develop, yet they also signify an area of extraordinary unmet need. Driven by a deeper understanding of the complex biology of the human brain and the emergence of validated molecular targets for neuropsychiatric and neurodegenerative diseases, the field is beginning to make important strides. This panel will discuss the innovative drugs for conditions such as ALS, Alzheimer’s disease, schizophrenia, and depression that are now in and/or emerging from the drug development pipeline.

The Disruptors: The Next Wave of Promising Psychiatry and Neurology Drugs

Grand Ballroom